Impact of tissue-agnostic approvals on management of primary brain tumors.

Document Type

Article

Publication Date

3-2024

Publication Title

Trends in cancer

Abstract

Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been recently approved by FDA, driven by basket trials that have demonstrated their efficacy and safety across diverse tumor histology. However, the relative rarity of primary brain tumors (PBTs) has limited their representation in early trials of tissue-agnostic medications. Thus, consensus continues to evolve regarding utility of tissue-agnostic medications in routine practice for PBTs, a diverse group of neoplasms characterized by limited treatment options and unfavorable prognoses. We describe current and potential impact of tissue-agnostic approvals on management of PBTs. We discuss data from clinical trials for PBTs regarding tissue-agnostic targets, including BRAF

Volume

10

Issue

3

First Page

256

Last Page

274

DOI

10.1016/j.trecan.2023.11.005

ISSN

2405-8025

PubMed ID

38245379

Link to Full Text

Share

COinS